Arvinas, Inc. (NASDAQ:ARVN) Insider Noah Berkowitz Sells 8,658 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Arvinas Trading Up 3.3 %

Arvinas stock opened at $8.70 on Thursday. Arvinas, Inc. has a 1-year low of $7.91 and a 1-year high of $44.85. The firm has a market capitalization of $598.32 million, a PE ratio of -3.14 and a beta of 1.95. The firm’s 50 day simple moving average is $16.65 and its 200 day simple moving average is $21.50.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the company earned ($2.53) EPS. Research analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of Arvinas

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in shares of Arvinas during the fourth quarter worth about $28,000. KBC Group NV grew its stake in Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares in the last quarter. Quantbot Technologies LP increased its holdings in shares of Arvinas by 147.3% in the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas during the 4th quarter valued at $171,000. Finally, Tema Etfs LLC bought a new stake in shares of Arvinas during the 4th quarter worth $227,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on ARVN. Bank of America dropped their target price on shares of Arvinas from $54.00 to $28.00 and set a “buy” rating on the stock in a research note on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Guggenheim decreased their target price on Arvinas from $57.00 to $32.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Citigroup dropped their price target on Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, March 7th. Finally, Wedbush lowered Arvinas from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.47.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.